PROMIS NEUROSCIENCES INC. Increase (Decrease) in Accounts Payable
PROMIS NEUROSCIENCES INC. (PMN) reported Increase (Decrease) in Accounts Payable of -$749.94 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $76.65K, a 95.15% decline year-over-year.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$826.59K.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$1.67M, a 1128.23% decline year-over-year.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.43M.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for fiscal 2025 was $805.95K.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for fiscal 2024 was -$6.11M, a 223.02% decline from fiscal 2023.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for fiscal 2023 was $4.96M, a 85.49% increase from fiscal 2022.
- PROMIS NEUROSCIENCES INC. increase (decrease) in accounts payable for fiscal 2022 was $2.68M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$749.94K 10-Q · filed 2026-08-13 | -$2.42M derived: sum of 3 quarters · filed 2026-08-13 | -$986.70K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$826.59K 10-Q · filed 2026-05-12 | -$2.49M derived: sum of 2 quarters · filed 2026-05-12 | -$1.06M derived: sum of 3 quarters · filed 2026-05-12 | $516.66K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$236.76K derived: sum of 2 quarters · filed 2026-03-25 | $1.34M derived: sum of 3 quarters · filed 2026-08-13 | $805.95K 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.01M derived: sum of 2 quarters · filed 2026-08-13 | $2.47M 10-Q · filed 2025-11-12 | $2.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.04M 10-Q · filed 2026-08-13 | $1.20M derived: sum of 3 quarters · filed 2026-08-13 | $765.01K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$537.30K 10-Q · filed 2026-05-12 | -$375.07K derived: sum of 2 quarters · filed 2026-05-12 | -$815.00K derived: sum of 3 quarters · filed 2026-05-12 | -$203.43K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $162.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$277.70K derived: sum of 2 quarters · filed 2026-03-25 | $333.87K derived: sum of 3 quarters · filed 2026-03-25 | -$6.11M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$439.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $171.64K derived: sum of 2 quarters · filed 2025-11-12 | -$6.27M 10-Q · filed 2025-11-12 | -$6.74M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $611.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$5.83M 10-Q · filed 2025-08-13 | -$6.30M derived: sum of 3 quarters · filed 2025-08-13 | -$5.68M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$6.44M 10-Q · filed 2025-05-12 | -$6.92M derived: sum of 2 quarters · filed 2025-05-12 | -$6.29M derived: sum of 3 quarters · filed 2025-05-12 | -$5.48M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$475.98K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $147.94K derived: sum of 2 quarters · filed 2025-03-31 | $960.83K derived: sum of 3 quarters · filed 2025-03-31 | $4.96M 10-K · filed 2025-03-31 |
| 2023-09-30 | $623.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.44M derived: sum of 2 quarters · filed 2024-11-14 | $5.44M 10-Q · filed 2024-11-14 | $6.60M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $812.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.82M 10-Q · filed 2024-08-08 | $5.97M derived: sum of 3 quarters · filed 2024-08-08 | $7.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.00M 10-Q · filed 2024-05-14 | $5.16M derived: sum of 2 quarters · filed 2024-05-14 | $6.19M derived: sum of 3 quarters · filed 2024-05-14 | $6.45M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.18M derived: sum of 2 quarters · filed 2024-04-01 | $2.45M derived: sum of 3 quarters · filed 2024-04-01 | $2.68M 10-K · filed 2024-04-01 |
| 2022-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.29M derived: sum of 2 quarters · filed 2023-11-14 | $1.52M 10-Q · filed 2023-11-14 | $1.47M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $264.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $491.64K 10-Q · filed 2023-08-14 | $443.44K derived: sum of 3 quarters · filed 2023-08-14 | $672.29K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $226.87K 10-Q · filed 2023-05-15 | $178.66K derived: sum of 2 quarters · filed 2023-05-15 | $407.52K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$48.20K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $180.66K derived: sum of 2 quarters · filed 2023-03-08 | -$31.65K 10-K · filed 2023-03-08 | |
| 2021-09-30 | $228.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $16.55K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$212.31K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |